Patents by Inventor Pier Adelchi Ruffini

Pier Adelchi Ruffini has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HOMODIMERIC PROTEIN CONSTRUCTS
    Publication number: 20230065226
    Abstract: The present invention relates to novel recombinant fusion proteins, such as human antibody-based molecules called Vaccibodies, which are able to trigger both a T cell- and B cell immune response. The present invention also relates to a method of treating a cancer or an infectious disease by means of these specific fusion proteins.
    Type: Application
    Filed: September 22, 2022
    Publication date: March 2, 2023
    Applicant: Nykode Therapeutics ASA
    Inventors: Pier Adelchi Ruffini, Bjarne Bogen, Agnete Brunsvik Fredriksen
  • Homodimeric protein constructs
    Patent number: 11479605
    Abstract: The present invention relates to novel recombinant fusion proteins, such as human antibody-based molecules called Vaccibodies, which are able to trigger both a T cell- and B cell immune response. The present invention also relates to a method of treating a cancer or an infectious disease by means of these specific fusion proteins.
    Type: Grant
    Filed: February 7, 2020
    Date of Patent: October 25, 2022
    Assignee: Nykode Therapeutics ASA
    Inventors: Pier Adelchi Ruffini, Bjarne Bogen, Agnete Brunsvik Fredriksen
  • HOMODIMERIC PROTEIN CONSTRUCTS
    Publication number: 20200239568
    Abstract: The present invention relates to novel recombinant fusion proteins, such as human antibody-based molecules called Vaccibodies, which are able to trigger both a T cell- and B cell immune response. The present invention also relates to a method of treating a cancer or an infectious disease by means of these specific fusion proteins.
    Type: Application
    Filed: February 7, 2020
    Publication date: July 30, 2020
    Applicant: Vaccibody AS
    Inventors: Pier Adelchi Ruffini, Bjarne Bogen, Agnete Brunsvik Fredriksen
  • Homodimeric protein constructs
    Patent number: 10590195
    Abstract: The present disclosure relates to recombinant fusion proteins, such as human antibody-based molecules called Vaccibodies, which are able to trigger both a T cell- and B cell immune response. The present disclosure also relates to a method of treating a cancer or an infectious disease by means of these specific fusion proteins.
    Type: Grant
    Filed: June 24, 2011
    Date of Patent: March 17, 2020
    Assignee: VACCIBODY AS
    Inventors: Pier Adelchi Ruffini, Bjarne Bogen, Agnete Brunsvik Fredriksen
  • IL-8 INHIBITORS FOR USE IN THE TREATMENT OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY
    Publication number: 20190015391
    Abstract: The present invention relates to IL-8 inhibitor compounds, preferably dual CXCR1/CXCR2 receptor inhibitors, useful in the treatment and/or prevention of chemotherapy-induced neuropathy, preferably in the treatment and/or prevention of chemotherapy-induced peripheral neuropathy (CIPN) or chemotherapy-induced optic neuropathy.
    Type: Application
    Filed: January 13, 2017
    Publication date: January 17, 2019
    Inventors: Laura BRANDOLINI, Pier Adelchi RUFFINI, Marcello ALLEGRETTI
  • HOMODIMERIC PROTEIN CONSTRUCTS
    Publication number: 20130336971
    Abstract: The present disclosure relates to recombinant fusion proteins, such as human antibody-based molecules called Vaccibodies, which are able to trigger both a T cell- and B cell immune response. The present disclosure also relates to a method of treating a cancer or an infectious disease by means of these specific fusion proteins.
    Type: Application
    Filed: June 24, 2011
    Publication date: December 19, 2013
    Applicant: VACCIBODY AS
    Inventors: Pier Adelchi Ruffini, Bjarne Bogen, Agnete Brunsvik Fredriksen
  • HOMODIMERIC PROTEIN CONSTRUCTS
    Publication number: 20130171140
    Abstract: The present disclosure relates to recombinant fusion proteins, such as human antibody-based molecules called Vaccibodies, which are able to trigger both a T cell- and B cell immune response. The present disclosure also relates to a method of treating a cancer or an infectious disease by means of these specific fusion proteins.
    Type: Application
    Filed: June 24, 2011
    Publication date: July 4, 2013
    Applicant: VACCIBODY AS
    Inventors: Pier Adelchi Ruffini, Bjarne Bogen, Agnete Brunsvik Fredriksen